Silver Book Fact

Fact image

The Impact of Personalized Medicine on Cancer Survival in Years

Munoz, J and R Kurzrock. Targeted Therapy in Rare Cancers: Adopting the orphans. Nat Rev Clin Oncol. 2012; 9(11): 631-42. http://www.ncbi.nlm.nih.gov/pubmed/22965154

Reference

Title
Targeted Therapy in Rare Cancers: Adopting the orphans
Publication
Nat Rev Clin Oncol
Publication Date
2012
Authors
Munoz, J and R Kurzrock
Volume & Issue
Volume 9, Issue 11
Pages
631-42
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Virtual colonoscopy is more efficient at detecting cancerous polyps than standard colonoscopy without imaging, and costs $500-$1,500 less.  
  • Colorectal Cancer Screening: Trends, 2003-2006  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • Imatinib, the first chemical agent to target a cancer-specific protein, improved 5-year survival rates for chromosome-positive chronic myelogenous leukemia (CML) from 17% in the mid-1970s to 63% in 2007.  
  • Since 1975, the five year survival rate for breast cancer patients has increased by 40 percent.